Journal ArticleDOI
Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
Stefan S. Bielack,Beate Kempf-Bielack,Günter Delling,G. Ulrich Exner,Silke Flege,Knut Helmke,Rainer Kotz,Mechthild Salzer-Kuntschik,M. Werner,Winfried Winkelmann,Andreas Zoubek,Heribert Jürgens,Kurt Winkler +12 more
Reads0
Chats0
TLDR
Axial tumor site, male sex, and a long history of symptoms were associated with poor response to chemotherapy in univariate and multivariate analysis.Abstract:
PURPOSE: To define prognostic factors for response and long-term outcome for a wide spectrum of osteosarcomas, extending well beyond those of the typical young patient with seemingly localized extremity disease. PATIENTS AND METHODS: A total of 1,702 consecutive newly diagnosed patients with high-grade osteosarcoma of the trunk or limbs registered into the neoadjuvant studies of the Cooperative Osteosarcoma Study Group before July 1998 were entered into an analysis of demographic, tumor-related, and treatment-related variables, response, and survival. The intended therapeutic strategy included preoperative and postoperative chemotherapy with multiple agents as well as surgery of all operable lesions. RESULTS: Axial tumor site, male sex, and a long history of symptoms were associated with poor response to chemotherapy in univariate and multivariate analysis. Actuarial 10-year overall and event-free survival rates were 59.8% and 48.9%. Among the variables assessable at diagnosis, patient age (actuarial 10-y...read more
Citations
More filters
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
TL;DR: Lymphedema is a common complication after treatment for breast cancer and factors associated with increased risk of lymphedEMA include extent of axillary surgery, axillary radiation, infection, and patient obesity.
Journal ArticleDOI
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
TL;DR: Biologic, preclinical, and clinical trial efforts will be described along with future international collaborative strategies to improve outcomes for patients who develop this challenging tumor.
Journal ArticleDOI
Osteosarcoma treatment - where do we stand? A state of the art review.
TL;DR: The current state of the art of systemic osteosarcoma therapy is reviewed by focusing on the experiences of cooperative osteosARcoma groups, shedding light on questions and challenges posed by the aggressiveness of the tumor, and potential future directions that may be critical to progress in the prognosis of high-grade osteosArcoma.
Journal ArticleDOI
Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
Leo Kager,Andreas Zoubek,Ulrike Pötschger,Ulrike Kastner,Silke Flege,Beate Kempf-Bielack,Detlev Branscheid,Rainer Kotz,Mechthild Salzer-Kuntschik,Winfried Winkelmann,Gernot Jundt,Hartmut Kabisch,Peter Reichardt,Heribert Jürgens,Helmut Gadner,Stefan S. Bielack +15 more
TL;DR: The number of metastases at diagnosis and the completeness of surgical resection of all clinically detected tumor sites are of independent prognostic value in patients with proven primary metastatic osteosarcoma.
Journal ArticleDOI
Biology and Therapeutic Advances for Pediatric Osteosarcoma
TL;DR: The authors review the state of the art management for patients with osteosarcoma in North America and Europe including the use of limb-salvage procedures and reconstruction as well as discuss the etiologic and biologic factors associated with tumor development.
References
More filters
Journal ArticleDOI
Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients
Stefan S. Bielack,Beate Kempf-Bielack,D. Schwenzer,T. Birkfellner,Günter Delling,Volker Ewerbeck,G. U. Exner,N. Fuchs,Ulrich Göbel,Norbert Graf,U. Heise,K. Helmke,A. R. von Hochstetter,Heribert Jürgens,Rainer Maas,N. Münchow,M. Salzer-Kuntschik,Jörn Treuner,U. Veltmann,M. Werner,W. Winkelmann,Andreas Zoubek,Rainer Kotz +22 more
TL;DR: Intensive multiagent chemotherapy and delayed surgery for localized extremity osteosarcoma led to excellent oncologic results in the COSS- studies, and giving doxorubicin and cisplatin by continuous infusions did not result in discernible prognostic disadvantages.
Journal ArticleDOI
Prognostic factors in osteosarcomas. A regression analysis
Søren M. Bentzen,Hans Skovgaard Poulsen,S. Kaae,O. Myhre Jensen,H. Johansen,H. T. Mouridsen,Søren Daugaard,C. Arnoldl +7 more
TL;DR: A multivariate regression analysis of survival data was performed on the retrospective material of 184 osteosarcoma patients treated at the Aarhus and Copenhagen oncology centers, Denmark, from 1963 to 1984, finding that children, adolescents, and adults ages 5 to 25 years had significantly poorer prognosis than young adults 25 to 30 years of age.
Journal ArticleDOI
Osteosarcoma of the limbs: report of the EORTC-SIOP 03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation
J. M. V. Burgers,M. van Glabbeke,A. Busson,P. Cohen,André Mazabraud,J. S. Abbatucci,Chantal Kalifa,M. Tubiana,Jean Lemerle,P. A. Voǔte,A. van Oosterom,A. Pons,T. Wagener,B. van der Werf-Messing,R. Somers,Nicole Duez +15 more
TL;DR: The European Organization for Research on Treatment of Cancer (EORTC) trial 20781, concerning osteosarcoma of the limbs, provided the same survival as the adjuvant chemotherapy given in that time.
Journal ArticleDOI
Targeted Radiotherapy of Osteosarcoma Using 153Sm-Edtmp: A new promising approach
TL;DR: A 35-year-old male with a primary osteosarcoma located in the first lumbar vertebra relapsed with progressive back pain after conventional treatment modalities had failed, and gave targeted radionuclide therapy using 153Sm-EDTMP gave substantial palliative effect.
Journal ArticleDOI
Prognostic factors in bone sarcomas.
Gunnar Sæter,Inkeri Elomaa,Y Wahlqvist,Thor Alvegård,Thomas Wiebe,Odd R. Monge,E Forrestier,Olesya Solheim +7 more
TL;DR: For an adolescent patient with non-metastatic extremity disease, there is no consensus regarding prognostic factors at initial presentation, and currently there is thus no established method for dividing them into high- and low risk groups for the purpose of treatment differentiation.